Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors with Significant Losses to Contact the Firm Before November 2, 2026

New York, New York--(Newsfile Corp. - September 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER : If you are a member of the proposed Class, you may move the court no later than November 2, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. On June 30, 2026, before the market opened, according to the complaint Unicycive disclosed that the FDA had issued a Complete Response Letter ("CRL") regarding the Company's resubmitted New Drug Application for its kidney disease therapy, oxylanthanum carbonate or OLC, identifying the "same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025. On this news, Unicycive's stock price fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026, on unusually heavy trading volume. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices, (2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies, and (3) that there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices. WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America —the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors , and a $475 million settlement in In re Merrill Lynch . For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. https://www.kaplanfox.com/case/unicycive-therapeutics-inc-nasdaq-uncy-class-action-lawsuit-learn-more-now/ To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313993 Source: Kaplan Fox & Kilsheimer LLP